Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27099782 | 1.00 | HTR2A (0.59) | HTR2AOPRM1SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL27225389 | 1.00 | HTR2A (0.59) | HTR2AOPRM1SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL28298506 | 0.89 | HTR2A (0.49) | HTR2AOPRM1SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL3438951 | 0.88 | HTR2A (0.50) | HTR2AOPRM1SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL19122010 | 0.88 | HTR2A (0.50) | HTR2AOPRM1SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL737635 | 0.87 | OPRM1 (0.61) | HTR2AOPRM1CYP2D6OPRK1OPRL1 | |
| Hydrochloric Acid SCHEMBL8587704 | 0.86 | HTR2A (0.48) | HTR2AOPRM1SLC6A2SLC6A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL10007993 | 0.85 | OPRM1 (0.59) | HTR2AOPRM1CYP2D6OPRK1OPRL1 | |
| SCHEMBL16488091 | 0.82 | HTR2A (0.45) | HTR2AOPRM1SLC6A2SLC6A3OPRK1 | |
| SCHEMBL24685352 | 0.82 | SLC6A2 (0.53) | HTR2AOPRM1SLC6A2SLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007672-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12491185-B2 | Inhibitors of mPTP | NRG THERAPEUTICS LTD (GB) | 2025-12-09 | — | — | US | disclosed |
| EP-4652162-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| EP-4608839-A1 | SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS | Protego Biopharma, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608834-A1 | SPIROCYCLE CONTAINING PYRIDINE COMPOUNDS | Protego Biopharma, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608838-A1 | SPIROCYCLE CONTAINING PYRIDONE COMPOUNDS | Protego Biopharma, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250177397-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| WO-2025010311-A1 | UREA-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-01-09 | — | — | WO | disclosed |
| WO-2024153946-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2024-07-25 | — | — | WO | disclosed |
| US-20240174672-A1 | Spirocycle Containing Pyridone Compounds | PROTEGO BIOPHARMA, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-109715155-A | blood brain barrier-penetrating agent dopamine- β -hydroxylase inhibitors | 巴尔-波特拉及康邦亚股份有限公司 | 2019-05-03 | — | — | CN | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
| US-9403775-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| WO-2016100940-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20130184320-A1 | Imine Compounds | BASF SE (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491185-B2 | Inhibitors of mPTP | PARK7, PINK1, SNCA | HTR2A 289/4885OPRM1 39/4885SLC6A2 45/4885 |
| US-20240174672-A1 | Spirocycle Containing Pyridone Compounds | TTR, BCL6, PLPBP | HTR2A 2162/4885OPRM1 4596/4885SLC6A2 3647/4885 |
| US-20250177397-A1 | INHIBITORS OF MPTP | PARK7, PINK1, SNCA | HTR2A 289/4885OPRM1 39/4885SLC6A2 45/4885 |
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | HTR2A 3002/4885OPRM1 1028/4885SLC6A2 4708/4885 |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | HTR2A 136/4885OPRM1 264/4885SLC6A2 400/4885 |
| US-20260007672-A1 | INHIBITORS OF MPTP | PARK7, SNCA, CYC1 | HTR2A 793/4885OPRM1 14/4885SLC6A2 85/4885 |
| US-20130184320-A1 | Imine Compounds | INMT, PNMT, IPO5 | HTR2A 2893/4885OPRM1 3285/4885SLC6A2 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.